Should You Buy Bionano Genomics in April?
Investors had high hopes for Bionano Genomics (NASDAQ: BNGO) in the first few weeks of the year. The company highlighted the progress and strengths of its optical genome mapping (OGM) technology at a five-day symposium. Then Bionano progressively raised $335 million in operations including public stock offerings. As a result, the stock soared more than 400% from the start of the year through a peak in February.
Since, the shares have dropped more than 50%. Now, the question is whether the share performance we saw a few weeks ago was an exception -- or whether this genome analysis company may produce steady gains over the long term. Let's take a closer look at the situation right now and what's ahead.
Image source: Getty Images.
Source Fool.com
